VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

ABSTRACT:

Background

The serum proteomic test VeriStrat has been shown to be able to classify advanced non-small cell lung cancer (NSCLC) patients for overall survival (OS) after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). In this study, VeriStrat was evaluated as a pre-treatment stratification tool in patients with advanced stage NSCLC for treatment with the combination of erlotinib and sorafenib, considering both OS and progression-free survival (PFS) as end points.

Methods

Serum samples from 50 patients treated within the context of a phase II trial of first-line erlotinib and sorafenib were analysed with VeriStrat, a fully locked mass spectrometry-based test that identifies patients likely to have good or poor outcome on EGFR therapy b

SUBMITTER: Kuiper JL 

PROVIDER: S-EPMC3505013 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature